Investor Presentation First Nine Months of 2022
137
Investor presentation First nine months of 2022
Total Rybelsus® TRx volume is steadily growing in the US
NAO
RybelsusⓇ and SGLT-2i¹ uptake in the US² since respective launches
TRX count
(000s)
100
Rybelsus® TRX
SGLT-2i TRX
82
In first nine months of 2022, RybelsusⓇ sales account
for 21% share of growth of NAO sales
•
Successful RybelsusⓇ launch despite COVID-19
impacting the first year of launch
RybelsusⓇ TRX continues to steadily increase
80
60
60
60
40
40
20
20
62
тури
65
93
124
155
Time since launch (weeks)
1SGLT-2i is an average of empagliflozin and canagliflozin script count. 2RybelsusⓇ is based on Oct 2019 focus launch. Each data points represents a rolling four-week average.
Note: TRx: Total prescription data; NAO: North America Operations; Source: IQVIA Xponent, Weekly ending 14 Oct 2022
0
0
31View entire presentation